The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis

Authors: Ribatti D.; Vacca A.; Roncali L.; Dammacco F.

Source: Current Pharmaceutical Biotechnology, Volume 1, Number 1, July 2000 , pp. 73-82(10)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Anti-angiogenesis, i.e.inhibition of blood vessel growth, is being investigated as a way to prevent the growth of tumors and other angiogenesis-dependent diseases. Pharmacological inhibition interferes with the angiogenic cascade or the immature neovasculature with synthetic or semi-synthetic substances, endogenous inhibitors or biological antagonists. The chick embryo chorioallantoic membrane (CAM) is an extraembryonic membrane commonly used in vivo to study both new vessel formation and its inhibition in response to tissues, cells, or soluble factors. Angiogenesis or anti-angiogenesis is evaluated quantitatively or semiquantitatively. The fields of application of CAM in the study of anti-angiogenesis, including our personal experience, are illustrated in this paper.

Keywords: Anti angiogenesis; Inhibition of blood vessel growth; In ovo method; In vitro utilization; Endostatin

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1389201003379040

Publication date: 2000-07-01

More about this publication?

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.